Just Thrive
Spore-Based Probiotic · 4-Strain Bacillus
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
2 human trials, about 20 studies, ~26 participants. The written rationale for this grade is still being prepared.
- FDA
- Marketed as supplement
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Some Bacillus species are naturally antibiotic-resistant and produce bacteriocins (natural antibiotics that can kill competing bacteria); the foundational Hong 2008 safety paper found B. indicus carried clindamycin resistance above EFSA breakpoints and flagged it for further study, while concluding the species were broadly safe for oral use. Independent reviewers note sporadic case reports of Bacillus (for example B. clausii) opportunistic infection in critically ill or immunocompromised people, especially after recent antibiotics, and that B. indicus HU36 has little human data. The theoretical concern that dominant spore-formers could reduce microbiome diversity is unresolved. Anyone who is pregnant, immunocompromised, critically ill, or on antibiotics, and anyone considering a probiotic for a child or for a specific medical condition, should consult a qualified healthcare provider before use rather than self-treating.
Just Thrive is a direct-to-consumer spore-based probiotic launched in 2013 by former pharmaceutical-industry executives Tina Anderson (a former trial lawyer and in-house counsel) and her husband Billy Anderson, and based on strains developed by Professor Simon Cutting at Royal Holloway, University of London (now assigned to SporeGen). It contains four Bacillus strains, B. subtilis HU58, B. indicus HU36, B. coagulans SC-208, and B. clausii SC-109, that form heat- and acid-resistant endospores, a genuine survivability advantage over fragile Lactobacillus products. Just Thrive is the retail sibling of the practitioner-market MegaSporeBiotic (from Microbiome Labs), which adds a fifth strain, B. licheniformis; the two share most strains but are not identical. The company reports that B. indicus HU36 uniquely produces carotenoid antioxidants in the gut, a claim that independent scientists note has no confirming human study.
Spore-based survivability is the strongest argument against fragile Lactobacillus products.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
What people get wrong
Often saidSpore probiotics are categorically superior to all others, and traditional probiotics do not work
ActuallyThe survivability advantage of spore-formers is real, but Lactobacillus, Bifidobacterium, and specific well-studied Bacillus strains (for example B. coagulans GBI-30 and B. subtilis DE111) carry indication-specific human RCT evidence. Independent microbiome scientist Lucy Mailing, PhD argues selection should be by strain and clinical merit, not category. The traditional-probiotics-do-not-work framing is marketing, not science.
Often saidThe McFarlin study proves Just Thrive works
ActuallyThe most-cited trial (McFarlin 2017) was a genuine randomized, double-blind, placebo-controlled design but randomized only 26 responders after screening 75, was partly funded by Microbiome Labs, and tested the 5-strain MegaSporeBiotic formulation, not the 4-strain retail Just Thrive. It is a small, supplier-linked, hypothesis-generating signal on a related formulation, not brand-verified proof.
Often saidB. indicus HU36 delivers proven antioxidants in your gut
ActuallyThe company reports HU36 produces carotenoids such as lycopene, lutein, and astaxanthin in the intestine. Independent scientists note there is no published human study confirming that B. indicus HU36 actually produces measurable antioxidants in people; the claim rests on the strain's in-vitro carotenoid capacity.
Often saidNear-100 percent survivability equals near-100 percent effectiveness
ActuallyEndospores do survive stomach acid far better than vegetative Lactobacillus, so the delivery claim is well grounded. Better delivery is not the same as better clinical outcomes, and survival to the gut does not by itself establish that a given strain colonizes or produces a therapeutic effect.
Who profits, and who pushes back
Lucy Mailing, PhD
There is no research to confirm that Bacillus indicus HU36 produces antioxidants in humans, and the clinical studies behind these spore products were often not blinded or placebo-controlled and used hand-selected high-responder cohorts; I would still choose products with more well-established safety profiles and more rigorous research.
Hong, Cutting and colleagues (2008 safety assessment)
Bacillus indicus and B. subtilis should be considered safe for oral use, although the resistance of B. indicus to clindamycin requires further study.
Traditional-probiotic evidence reviewers
Decades of condition-specific RCTs exist for particular Lactobacillus and Bifidobacterium strains; spore products have a thinner, though growing, brand-verified human evidence base, and much of it is in-vitro gut-model or supplier-linked.
Dr. Tina Anderson
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Pharmacist; advocates strongly for spore-based over Lactobacillus. The survivability argument has scientific merit, but she sells the product, so the categorical superiority framing carries commercial context.
Spore-probiotic community
Growing adoption among those who distrust fragile refrigerated products.
Where the research comes from
Most of the published research on this comes from one place. 70% of it is from USA. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| USA | 70% |
| Other | 30% |
Research published from: USA.
How we got here
The spore-based Bacillus strains at the heart of Just Thrive trace not to the brand but to Professor Simon Cutting, often called the father of Bacillus probiotics, and his team at Royal Holloway, University of London, who isolated and characterized human-derived strains including B. subtilis HU58 and B. indicus HU36 (the HU denotes Holloway University, the SC denotes Simon Cutting). Ownership of those two strains was assigned to SporeGen. Cutting and colleagues published a foundational safety assessment (Hong 2008) concluding the species were safe for oral use. The commercial line grew from Microbiome Labs (co-founded by Kiran Krishnan, 2012), whose practitioner MegaSporeBiotic combined five Bacillus strains. Just Thrive, launched in 2013 by former pharmaceutical executives Tina and Billy Anderson, brought a four-strain retail version to the consumer market, building its identity around survivability and the unusual carotenoid-producing HU36 strain.
- 2008Hong, Cutting and colleagues publish a foundational safety assessment of B. subtilis and B. indicus as food probiotics
- 2012Microbiome Labs founded (Kiran Krishnan a co-founder); develops the 5-strain practitioner MegaSporeBiotic
- 2013Just Thrive launched by Tina and Billy Anderson as a 4-strain retail spore-based probiotic
- 2017SporeGen assigned ownership of B. subtilis HU58 and B. indicus HU36 from Royal Holloway; McFarlin publishes the small endotoxemia RCT on the 5-strain formulation
- 2020Marzorati and colleagues publish in-vitro SHIME gut-model work on the Bacillus strains
- 2023Catinean and colleagues publish a retrospective observational study associating the 5-strain formulation with faster mild-COVID symptom resolution
- 2024McFarlin publishes a small gene-expression RCT (n=20) on the 5-strain formulation reporting altered post-prandial GI-barrier and immunity mRNA
At a glance
- Strains
- 4 Bacillus species
- Survivability
- Near 100% to gut
- Shelf
- Room-temp stable
- Unique
- B. indicus makes carotenoids
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Just Thrive. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Flagship endotoxemia RCT: randomized, double-blind, placebo-controlled, 26 responders randomized from 75 screened, 5-strain formulation, 42 percent endotoxin and 24 percent triglyceride post-prandial reduction; partly funded by Microbiome Labs LLC
McFarlin et al., World Journal of Gastrointestinal Pathophysiology (PubMed)
Gene-expression follow-up RCT (n=20) on MegaSporeBiotic 5-strain formulation, altered post-prandial GI-barrier and immunity mRNA, funded by Novozymes/Novonesis
Retrospective observational mild-COVID study (n=120) on the 5-strain formulation, faster symptom and fever resolution; editorial support funded by Microbiome Labs, product named MegaSporeBiotic
Foundational safety assessment of B. subtilis and B. indicus as food probiotics; broadly safe for oral use, B. indicus clindamycin resistance flagged
Hong, Cutting et al., Journal of Applied Microbiology (Wiley/Oxford Academic)
Strain provenance: B. subtilis HU58 and B. indicus HU36 developed at Royal Holloway, University of London (Simon Cutting) and assigned to SporeGen
In-vitro SHIME gut-model evidence that the Bacillus strains altered microbial diversity and reduced antibiotic-induced dysbiosis
Independent scientific critique: no human study confirms HU36 antioxidant production; MegaSpore/Just Thrive studies often unblinded or high-responder-selected; strain-specific evaluation preferred
Company origin, 2013 launch, founders Tina and Billy Anderson described as former pharmaceutical executives, strains from Simon Cutting
Current retail Just Thrive 4-strain composition (B. subtilis HU58, B. indicus HU36, B. coagulans, B. clausii), survivability and HU36 carotenoid claims, Royal Holloway licensing
Tina Anderson professional background as former trial lawyer and in-house counsel for a family pharmaceutical company (not a pharmacist)